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Phagocytosis of tubercle bacilli by antigen-presenting cells in human lung alveoli initiates a complex infection process by
Mycobacterium tuberculosis and a potentially protective immune response by the host. M. tuberculosis has devoted a large part
of its genome towards functions that allow it to successfully establish latent or progressive infection in the majority of infected
individuals. The failure of immune-mediated clearance is due to multiple strategies adopted by M. tuberculosis that blunt the
microbicidal mechanisms of infected immune cells and formation of distinct granulomatous lesions that diﬀer in their ability to
support or suppress the persistence of viable M. tuberculosis. In this paper, current understanding of various immune processes
that lead to the establishment of latent M. tuberculosis infection, bacterial spreading, persistence, reactivation, and waning or
elimination of latent infection as well as new diagnostic approaches being used for identiﬁcation of latently infected individuals
for possible control of tuberculosis epidemic are described.
1.Introduction
Tuberculosis (TB) has aﬄicted mankind from the time
immemorial. Evidence of spinal disease has been found
in Egyptian mummies of several thousand years BC and
references to TB are found in ancient Babylonian and
Chinese writings. Recent molecular genetic studies have
shown that Mycobacterium tuberculosis, the most common
cause of TB in humans worldwide, has a progenitor ∼3
millionyearsold[1].Mycobacteriumtuberculosisisamember
of the M. tuberculosis complex (MTBC) which includes six
other closely related species: M. bovis, M. africanum, M.
microti,M.pinnipedii,M.caprae,andM.canetti.Althoughall
MTBC members are obligate pathogens and cause TB, they
exhibit distinct phenotypic properties and host range. The
MTBC members are genetically extremely closely related, the
genome of M. tuberculosis shows <0.05% diﬀerence with M.
bovis, the latter species primarily infects cattle but can also
cause TB in other mammals including humans [2, 3].
Tuberculosis is one of the most prevalent infections of
human beings and a formidable public health challenge that
showslittle sign ofabating. The disease contributesconsider-
ably to illness and death around the world, exacting a heavy
toll on the world’s most vulnerable citizens. The current TB
epidemic is being sustained and fuelled by two important
factors: the human immunodeﬁciency virus (HIV) infection
and its association with active TB disease and increasing
resistance of Mycobacterium tuberculosis strains to the most
eﬀective (ﬁrst-line) anti-TB drugs [4]. Other contributing
factors include population expansion, poor case detection
andcureratesinimpoverishedcountries,activetransmission
in overcrowded hospitals, prisons, and other public places,
migration of individuals from high-incidence countries
due to wars or famine, drug abuse, social decay, and
homelessness. Active disease patients with sputum smear-
positive pulmonary TB are the main source of infection in
a community. Primary infection with M. tuberculosis leads to
clinicaldiseaseinonly ∼10%ofindividuals.Intheremaining
cases, the ensuing immune response arrests further growth
of M. tuberculosis. However, the pathogen is completely
eradicated in only ∼10% people, while the immune response
intheremaining ∼90%individualsonlysucceedsincontain-
ment of infection as some bacilli escape killing by blunting
the microbicidal mechanisms of immune cells (such as
phagosome-lysosome fusion, antigen presentation by MHC
class I, class II, and CD1 molecules, production of nitric
oxide,andotherreactivenitrogenintermediates)andremain
in nonreplicating (dormant or latent) state in old lesions.2 Clinical and Developmental Immunology
The process is termed as latent tuberculosis infection (LTBI),
and the dormant bacilli retain the ability to resuscitate and
to cause active TB if a disruption of immune response (as
in HIV infection) occurs. The World Health Organization
(WHO) has estimated that one-third of the total world
population is latently infected with M. tuberculosis and
5%–10% of the infected individuals will develop active TB
disease during their life time [4, 5]. However, the risk of
developing active disease is 5%–15% every year and lifetime
riskis∼50%inHIVcoinfectedindividuals[4,6].Mostofthe
active disease cases in low TB incidence countries arise from
this pool of latently infected individuals.
According to WHO estimates, 9.27 million new active
disease cases corresponding to an estimated incidence of
139 per 100,000 population occurred throughout the world
in 2007 [4]. Only 5.5 million of 9.27 million cases of TB
(new cases and relapse cases) were notiﬁed to national
tuberculosis programs of various countries, while the rest
were based on assessments of eﬀectiveness of surveillance
systems. The highest number of TB cases occurred in Asia
(55%) followed by Africa (31%). The highest incidence rate
(363 per 100,000 population) was recorded for the African
region, mainly due to high prevalence of HIV infection. The
sixmostpopulouscountriesofAsia(China,India,Indonesia,
Pakistan, Bangladesh, and Philippines) accounted for >50%
of all TB cases worldwide. An estimated 1.37 million (15%)
of incident TB cases in 2007 were coinfected with HIV.
Nearly 80% of the HIV-infected TB patients were living in
the African region [4]. Globally, 13.7 million total prevalent
TB cases were recorded in 2007 corresponding to 206 cases
per 100000 population that resulted in 1.756 million deaths
(including 456000 among TB patients coinfected with HIV)
[4]. Nearly 500000 cases of multidrug-resistant TB (MDR-
TB, deﬁned as infection with M. tuberculosis strains resistant
at least to the two most important ﬁrst-line drugs, rifampin
and isoniazid) occurred in 2007 [4]. By the end of 2008,
extensively drug-resistant TB (XDR-TB; deﬁned as MDR-
TB strains additionally resistant to a ﬂuoroquinolone and an
injectable agent such as kanamycin, amikacin, viomycin, or
capreomycin) has been found in 55 countries and territories
of the world [4]. While MDR-TB is diﬃcult and expensive to
treat, XDR-TB is virtually an untreatable disease in most of
the developing countries [7].
Population-based studies have shown that some indi-
viduals are more at risk of acquiring infection and devel-
oping active disease than others. Active transmission also
occurs more frequently in small households and crowded
places in countries with a high incidence of TB [8, 9].
Molecular epidemiological studies have shown that there
are distinct diﬀerences in the disease presentation and
population demographics in low TB incidence and high TB
incidence countries. In several African and Asian countries,
where the transmission of M. tuberculosis has been stable or
increased in the last few years, the incidence rate is highest
among young adults with most cases resulting from recent
episodes of infection or reinfection. On the contrary, in
low TB incidence countries of Western Europe and North
America, a higher proportion of cases occur in older patients
or among immigrants from high TB incidence countries
[8, 10]. Pulmonary TB accounts for >85% of active TB
cases in high TB incidence countries due to higher rates
of active transmission, while extrapulmonary TB is also
common in low TB incidence countries of the developed
world, particularly among HIV-infected individuals and
immigrants originating from TB endemic countries [11, 12].
2. Transmission of M. tuberculosis Infection
Tuberculosis is a communicable disease and patients with
pulmonary TB are the most important source of infection.
Infection is initiated by inhalation of droplet nuclei, which
are particles of 1–5μm in diameter containing M. tuberculo-
sis,expectoratedbypatientswithactivepulmonaryTB(open
TB), typically when the patient coughs. The droplet nuclei,
due to their small size, can remain suspended in the air for
several minutes to hours. The risk of infection (Figure 1)
is dependant on several factors such as the infectiousness
of the source case, the closeness of contact, the bacillary
load inhaled, and the immune status of the potential host
[8–10]. The primary route of infection involves the lungs.
Inhaled droplet nuclei avoid the defenses of the bronchi
due to their small size and penetrate into the terminal
alveoli where they are engulfed by phagocytic immune
cells (macrophages and dendritic cells). M. tuberculosis
can also infect nonphagocytic cells in the alveolar space
including M cells, alveolar endothelial, and type 1 and
type 2 epithelial cells (pneumocytes) [13–19]. In the early
phaseofinfection,M.tuberculosis,internalizedbyphagocytic
immune cells, replicates intracellularly, and the bacteria-
laden immune cells may cross the alveolar barrier to cause
systemic dissemination [14, 15]. The intracellular replication
and simultaneous dissemination of the pathogen to the pul-
monary lymph nodes and to various other extrapulmonary
sites occur prior to the development of the adaptive immune
responses. This exempliﬁes the extraordinary ability of M.
tuberculosis to establish a protected niche where they can
avoid elimination by the immune system and to persist
indeﬁnitely [20, 21].
In the vast majority of the infected individuals, an
eﬀective cell-mediated immune response develops 2–8 weeks
after infection that stops further multiplication of the
tubercle bacilli (Figure 1). The activated T lymphocytes,
macrophages, and other immune cells form granulomas
that wall oﬀ the growing necrotic tissue limiting further
replication and spread of the tubercle bacilli. Most of the
M. tuberculosis are killed in the caseating granulomas, and
disease progression is arrested. However, the pathogen is not
completely eradicated in some individuals as M. tuberculosis
hasevolvedeﬀectivestrategiestoevadetheimmuneresponse
resulting in survival and persistence of some bacilli in a
nonreplicating state in the host (LTBI) [8, 21, 22]. In support
of this hypothesis, M. tuberculosis has been cultured and
presence of M. tuberculosis DNA has been demonstrated
fromlungtissuesofindividualswhodiedfromotherdiseases
and who did not exhibit any pathological sign of TB disease
[23, 24]. Furthermore, a recent report showing transmission
of infection from father to son in Denmark in 1961 andClinical and Developmental Immunology 3
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Figure 1: Progression of natural course of events and outcome in an immunocompetent individual following exposure to droplet nuclei
containing M. tuberculosis expectorated by a source case of sputum smear-positive pulmonary (open) TB.
reactivation of latent infection in the son more than 30
years later (documented by molecular ﬁngerprinting of their
respective M. tuberculosis isolates) has indicated that the
survivingbacillimayremaindormantforalongtime(lasting
up to a lifetime) [25]. A subsequent defect in cell-mediated
immunity may result in reactivation of dormant bacilli caus-
ing active disease many years after the infection (reactivation
TB). The current understanding of the mechanisms leading
to the establishment of latent infection and the transition
back to active growth in reactivation of latent disease is
described below.
3.EntryMechanismsofM. tuberculosis
Infection with M. tuberculosis starts with phagocytosis of
the bacilli by phagocytic antigen-presenting cells in the
lung including alveolar macrophages and dendritic cells.
The recognition of pathogen-associated molecular patterns
(PAMP)byspeciﬁcpathogenrecognitionreceptors(PRRs)is
central to the initiation and coordination of the host innate
immune response [26]. M. tuberculosis internalized through
diﬀerent receptors may also have diﬀerent fate.
The M. tuberculosis or M. tuberculosis components are
recognized by host receptors that include Toll-like recep-
tors (TLRs), nucleotide-binding oligomerization domain-
(NOD-) like receptors (NLRs), and C-type lectins. The
C-type lectins include mannose receptor (CD207), the
dendritic cell-speciﬁc intercellular adhesion molecule grab-
bing nonintegrin (DC-SIGN) and Dectin-1 [27, 28]. Other
potential receptors include complement receptors, scaven-
ger receptors, surfactant protein A receptors (Sp-A), and
cholesterol receptors [29]. Some of these receptors (such
as TLRs) are expressed on both, immune cells (such as
macrophages, dendritic cells, B cells, and speciﬁc types of
T cells) and nonimmune cells (like ﬁbroblasts and epithelial
cells). The interaction of M. tuberculosis with TLRs initiates
an intracellular signaling cascade that culminates in a proin-
ﬂammatory response (beneﬁcial to the host); however, the
bacterium has also evolved strategies that can trigger signals
that dampen or modulate the innate immune response
(beneﬁcial to the pathogen). Other membrane bound PRRs
(CD207, DC-SIGN, and Dectin-1) contribute to the relay
of inﬂammatory signals while cytosolic PRRs (such as
Nod-like receptor) modulate host recognition of the path-
ogen [27, 28].4 Clinical and Developmental Immunology
The TLR engagement, particularly TLR2 and TLR4,
with M. tuberculosis/M. tuberculosis component is an early
event in the interaction of the pathogen with host cells
and TLR signaling is the main arm of the innate immune
response during M. tuberculosis infection [27, 28, 30]. The
TLR polymorphisms regulate the innate immune response
to mycobacterial lipopeptides and clinical susceptibility to
pathogens [31]. Typically, signals generated by the inter-
actions of TLRs with ligands on M. tuberculosis induce
the activation of proinﬂammatory and antimicrobial innate
immune response.
The M. tuberculosis cell envelope is composed of a cell
wall that is covered with a thick waxy mixture of lipids
and polysaccharides and is characterized by a high content
of mycolic acids. The most important M. tuberculosis cell
surface ligands that interact with TLRs and other receptors
include the 19 and 27kDa lipoproteins, 38kDa glycol-
ipoprotein, the lipomannan (LM) and mannose-capped li-
poarabinomannan (ManLAM) [32–34]. Other ligands
include LprA and LprG lipoproteins [35, 36] and, perhaps
also, surface-exposed mammalian cell entry (Mce) proteins
encoded by mce1 and mce3 operons [37–39]. The interaction
of M. tuberculosis ligand(s) with TLRs eventually results
in activation of nuclear transcription factor (NF)-κBa n d
production of proinﬂammatory cytokines such as tumor
necrosis factor (TNF)-α, interleukin (IL)-1, IL-12, chemok-
ines, and nitric oxide through either myeloid diﬀerentiation
primary response protein 88 (MyD88)-dependant or
MyD88-independent pathway [27, 34, 40, 41].
Restricting TLR-induced proinﬂammatory signals is
essential to avoid the risk of producing excessive inﬂamma-
tion that could damage host tissues. A family of receptor
tyrosine kinases termed Tyro3/Axl/Mer (TAM) provide a
negative feedback mechanism to both TLR-mediated and
cytokine-driven proinﬂammatory immune responses [42].
This property has been exploited by M. tuberculosis to its
advantage. The 19kDa lipoprotein of M. tuberculosis is an
agonist of the TLR2 and modulates the innate immunity and
antigen presenting cell function [32]. Studies have shown
that prolonged TLR2 signaling by lipoproteins of M. tuber-
culosis inhibits major histocompatibility complex (MHC)-II
expression and processing of antigens by macrophages [43,
44]. Thus, a subset of infected macrophages with decreased
antigen-presenting cellfunctionmay be unable topresent M.
tuberculosis antigens to CD4+ T cells resulting in insuﬃcient
activation of eﬀector T cells leading to evasion of immune
surveillance and creation of niches where M. tuberculosis
survives and persists [27, 32].
The mannose receptors interact with ManLAM present
in the cell envelop of M. tuberculosis.T h ep h a g o c y t o s i so f
tubercle bacilli by macrophages through mannose receptor is
associated with an anti-inﬂammatory response as ManLAM
inhibits mannose receptor-dependant IL-12 production.
This inhibition of macrophage response to M. tuberculosis
promotes infection and subsequent survival of M. tuber-
culosis in macrophages. The ManLAM exerts its eﬀects
on phagolysosome maturation by limiting phagosome-
lysosome fusion [45, 46].
4. Immune Response of the Host to
M. tuberculosis
The alveolar macrophages, after entry of M. tuberculo-
sis, produce inﬂammatory cytokines and chemokines that
serve as a signal for infection. The monocytes, neutrophils,
and lymphocytes migrate to the focal site of infection,
but they are unable to kill the bacteria eﬃciently. Dur-
ing this time, the bacilli resist the bactericidal mecha-
nisms of the macrophage (phagolysosome) by prevent-
ing phagosome-lysosome fusion, multiply in the phago-
s o m e ,a n dc a u s em a c r o p h a g en e c r o s i s[ 47]. The released
bacilli multiply extracellularly, are phagocytosed by another
macrophage that also fails to control the growth of M.
tuberculosis, and likewise are destroyed. In the meantime,
dendritic cells with engulfed bacilli mature, migrate to
the regional lymph node, and prime T cells (both CD4+
and CD8+) against mycobacterial antigens [48]. The spe-
ciﬁc immune response produces primed T cells which
migrate back to the focus of infection, guided by the
chemokines produced by the infected cells. The accumula-
tion of macrophages, T cells, and other host cells (dendritic
cells, ﬁbroblasts, endothelial cells, and stromal cells) leads
to the formation of granuloma at the site of infection
[49].
The granuloma formation walls oﬀ tubercle bacilli
from the rest of the lung tissue, limits bacterial spread,
and provides microenvironment for interactions among
macrophages and other cells of the immune system and the
cytokines produced by these cells. The CD4+ Tc e l l sp r o -
ducing interferon-γ (IFN-γ) recognize infected macrophages
presenting antigens from M. tuberculosis and kill them [50].
The infection progression is halted; however, some resistant
bacilli capable of surviving under the stressful conditions
generated by the host escape killing and enter a state
of dormancy and persist by avoiding elimination by the
immune system [22, 51, 52]. Recent studies have shown that
diﬀerences exist in the immunological response mounted
by diﬀerent individuals that lead to the formation of
physiologically distinct granulomatous lesions in individuals
exposed to M. tuberculosis. Some of these lesions suppress
(sterilizing immunity) while others promote the persistence
of viable M. tuberculosis in the microenvironment [53].
Low-dose infection of cynomolgus macaques that reproduce
the clinical characteristics of human latent TB leads to the
formationofatleasttwotypesoftuberculousgranuloma[54,
55]. Histopathological studies have shown that the classic
caseous granuloma are composed of epithelial macrophages,
neutrophils, and other immune cells surrounded by ﬁbrob-
lasts. The central caseous necrotic region in this type of
granuloma consists of dead macrophages/other cells and is
hypoxic with M. tuberculosis residing inside macrophages in
the hypoxic center [55, 56]. The other kind of granulomas
seen in latent tuberculosis in both humans and cynomolgus
macaques are ﬁbrotic lesions, composed almost exclusively
of ﬁbroblasts that contain very few macrophages [55].
However, it is not known at present whether M. tuberculosis
is located inside macrophages or in the ﬁbrotic area in these
lesions.Clinical and Developmental Immunology 5
The microenvironment of the granuloma (hypoxia, low
pH, presence of nitric oxide and carbon monoxide, etc.)
increases the expression of several M. tuberculosis genes
involved in dormancy induction [57–60]. Recent ﬁndings
of formation of spore-like structures in M. bovis BCG, M.
marinum, and M. smegmatis in response to prolonged sta-
tionary phase or nutrient starvation suggest that sporulation
may be a general mechanism for mycobacterial dormancy
[60–62]. The dormant bacilli can inhabit the granuloma
during the lifetime of the host, but are able to resuscitate
(or germinate) in the event of local immunodepression. The
latent infection in a person without overt signs of the disease
is indicated by the delayed-type hypersensitivity (DTH)
response to puriﬁed protein derivative (PPD) prepared from
culture ﬁltrates of M. tuberculosis (tuberculin skin test)
[8].
5.SpeciﬁcRoles of ImmuneCellsand
CytokinesinM. tuberculosis Infection
Studies in animal models and in humans have demonstrated
that a wide range of immune components are involved in
an eﬀective immune response against M. tuberculosis. These
include, beside macrophages and dendritic cells, αβ-T cells
(both CD4+ and CD8+), CD1 restricted T cells, γδ-T cells,
and cytotoxic T cells, as well as the cytokines produced by
these immune cells [22, 63, 64]. The most important among
these are CD4+ T cells and the cytokine IFN-γ. Although
CD4+ Tc e l l sa l o n gw i t hC D 8 + T cells and the natural
killer (NK) cells are the major producers of IFN-γ, studies
carried out in CD4+ deﬁcient mice have shown that it is the
early production of IFN-γ by CD4+ T cells and subsequent
activation of macrophages that determine the outcome of
infection [65, 66]. The CD4+ T cells also play other roles in
the defense against infection that is independent of IFN-γ
production. Depletion of CD4+ T cells was associated with
the reactivation of infection in a chronically infected mice
and resulted in increasing pathological features and death,
even though IFN-γ levels were still high due to a strong
response from CD8+ T cells and normal levels of inducible
nitric oxide synthase (iNOS) [67].
The CD4+ T cells carry out several functions that
are important to control infection in the granuloma.
These include apoptosis of infected macrophages through
Fas/Fas ligand interaction, production of other cytokines
( s u c ha sI L - 2a n dT N F - α), induction of other immune
cells (macrophages or dendritic cells) to produce other
immunoregulatory cytokines such as IL-10, IL-12, and IL-
15, and activation of macrophages through direct contact via
CD40 ligand [63, 66, 68, 69]. The CD4+ T cells also appear to
be critical for the cytotoxic function of CD8+ T cells that is
mediatedbyIL-15[66,70].IthasalsobeenshownthatCD4+
T cells can control the intracellular growth of M. tuberculosis
by a nitric oxide-dependent mechanism that is independent
ofIFN-γ production[66,71].Thus,CD4+ Tcells,inaddition
to early production of IFN-γ appear to have several other
secondary functions that are critical in the control of M.
tuberculosis infection.
The CD8+ T-cells, in addition to producing IFN-γ and
other cytokines, may also be cytotoxic for M. tuberculosis-
infected macrophages, and thus play an important role in
providing immunity to TB. The CD8+ T-cells can directly
kill M. tuberculosis via granulysin, and facilitate the control
of both the acute as well as chronic infection [66, 72]. The
abundant presence of M. tuberculosis-speciﬁc CD8+ Tc e l l s
in latently infected individuals shows that the CD8+ Tc e l l s
also have a role in the control of latent infection. This is
also supported by reactivation of latent infection following
depletion of CD8+ T cells in the Cornell model of latent TB
[73].
Studies in primate models of TB have shown that
unconventionalTcellssuchasCD1restrictedTcells,andγδ-
T cells also contribute to the protection against TB [64, 74,
75]. The CD1 restricted T cells recognize the glycolipids such
asLAMthatareabundantinthemycobacterialcellwallwhile
γδ-T cells recognize small metabolites containing phosphate
(phospholigands) [74]. Although it is well established that
mycobacterial antigens in the phagosome of macrophages or
dendritic cells are picked up by the MHC class II molecules
and presented to CD4+ T cells, studies have shown that the
phagosomal membrane is also equipped with the MHC class
I processing machinery [76, 77]. Also, CD1 proteins have
the capability to present lipid antigens and lipopeptides to T
cells, and thus play important roles in the immune response
against lipid-rich M. tuberculosis [75, 78, 79]. Further, the
vesicles formed due to apoptosis of M. tuberculosis-infected
macrophages and containing mycobacterial antigens such
as ManLAM, lipoproteins, and so forth are taken up by
dendritic cells and presented to the T cells through the MHC
class I and CD1 molecules [75, 78, 80].
The IFN-γ is the key cytokine for a protective immune
response against M. tuberculosis.H u m a n sa n dm i c ed e f e c t i v e
in IFN-γ or IFN-γ receptor genes are more susceptible to
M. tuberculosis infection [63, 66, 81]. The IFN-γ,p r o d u c e d
m a i n l yb yC D 4 +,C D 8 + T cells, and the NK cells, synergizes
with TNF-α and activates macrophages to kill intracellular
bacilli. The IFN-γ also augments antigen presentation,
leading to recruitment of CD4+ T-cells and/or cytotoxic
CD8+ T-cells, which participate in mycobacterial killing
and also prevents exhaustion of memory T cells [63, 82].
Furthermore, IFN-γ induces the transcription of more than
200 genes in macrophages including the upregulation of
MHCclassIIexpression andtheproductionofantimicrobial
eﬀectors such as oxygen radicals and nitric oxide. A major
eﬀectormechanismresponsiblefortheantimicrobialactivity
of IFN-γ in association with TNF-α is the induction of
the production of nitric oxide and other reactive nitrogen
intermediates (RNI) by macrophages via iNOS [63, 66, 83].
However, some M. tuberculosis factor(s), such as the 19-kDa
lipoprotein, have the potential to attenuate the response of
macrophages to IFN-γ by blocking the transcription of a
subset of IFN-γ-responsive genes (Table 1)[ 44, 84, 85].
TNF-α, produced by macrophages, dendritic cells, and
T-cells, is another cytokine that has a major protective role
against M. tuberculosis infection both in mice and humans
[104, 105]. Paradoxically, TNF-α also contributes signiﬁ-
cantly to the development of immunopathology associated6 Clinical and Developmental Immunology
Table 1:SomeimportantM.tuberculosisfactorsthatmodulatetheinnateimmuneresponseandpromotepersistenceofthepathogenleading
to latent tuberculosis infection.
M. tuberculosis component Immune cell process inhibited/aﬀected Reference(s)
19kDa Lipoprotein (LpqH) MHC class II expression and antigen presentation [32, 44, 85–87]
19kDa Lipoprotein (LpqH) Phagosomal processing by MHC class I pathway [88]
Mannose capped lipoarabinomannan Phagolysosome biogenesis [46, 89, 90]
Mannose capped lipoarabinomannan MHC class II expression and antigen presentation [85, 90]
Mannose capped lipoarabinomannan IL-12 secretion of dentritic cells/macrophages [45, 90]
Mannose capped lipoarabinomannan Apoptosis of macrophages [90, 91]
Trehalose dimycolate (cord factor) Phagolysosome biogenesis [92, 93]
Trehalose dimycolate (cord factor) MHC class II expression and antigen presentation [94]
6-kDa early secreted antigenic target (ESAT-6) Pathogen containment in phagolysosome/macrophage [95–97]
ESX-1 secreted proteins Macrophage proinﬂammatory cytokine response [98]
Serine/threonine protein kinase G (PknG) Phagolysosome biogenesis [99, 100]
Lipid phosphatase (SapM) Phagolysosome biogenesis [101]
Lipoprotein LprA MHC class II expression and antigen presentation [36]
Lipoprotein LprG MHC class II expression and antigen presentation [35]
Secretion system SecA2 Apoptosis of macrophages and dendritic cells [102]
Superoxide dismutase (SodA) Apoptosis of macrophages and dendritic cells [102]
NADH dehydrogenase (NuoG) Apoptosis of macrophages and dendritic cells [103]
with TB [52]. Mice deﬁcient in TNF-α or TNF-α receptors
are more susceptible to mycobacterial infections [104]. This
cytokine is involved in both immune and immunomodula-
tory responses and acts in synergy with IFN-γ to enhance
the expression of iNOS and the antimycobacterial activity
of macrophages [63, 83]. TNF-α also initiates cell migration
and formation of microbicidal granulomas while disruption
of TNF-α responses leads to overgrowth of the mycobacterial
pathogens [63, 66]. The TNF-α produced by the infected
macrophages induces the expression of chemokines, such
as IL-8, MCP-1, and RANTES which provide signals for
migration of immune cells to the sites of M. tuberculosis
infection[106].BothTcell-andmacrophage-derivedTNF-α
are required for suﬃcient and long-term protection against
M. tuberculosis infection [107]. The phenolic glycolipid, a
virulence factor in the cell wall of a hypervirulent strain
of M. tuberculosis (W-Beijing family) inhibits the release
of pro-inﬂammatory cytokines TNF-α, IL-6 and IL-12 by
macrophages [108].
The importance of IL-12 is also evident from increased
susceptibility of mice and humans deﬁcient in IL-12
responsestomycobacterialinfections[109]. Individuals with
defects in the production of IL-12 or its receptor are highly
susceptible to active TB disease [110]. The T-cell-derived
cytokines, IFN-γ and TNF-α, are produced abundantly by
activated CD4+ T cells under the inﬂuence of IL-12, and the
role of IFN-γ and TNF-α in activating and augmenting the
microbicidal eﬀector functions of phagocytic cells during a
protectiveimmune response againstM.tuberculosisinfection
is well established [63, 66, 83].
6. Antigen PresentationPathways
and Their Modulation by
M. tuberculosis Components
The tubercle bacilli reside in the phagosome soon after
their entry inside alveolar macrophages and dendritic cells.
The priming of CD4+ T cells for a protective immune
responserequiresthepresentationofM.tuberculosisantigens
through MHC class II pathway. The phagosomal membrane
is also equipped with the MHC class I processing machinery
[74, 77]. Further, mycobacterial glycolipids, lipids, and
other phospholigands may also be presented to the T cells
[78, 80]. Some M. tuberculosis factors particularly those
associated with the cell wall modulate antigen-processing
pathways by MHC class I, MHC class II, and CD1 molecules
[28, 63, 111]. The ManLAM, trehalose 6,6
 -dimycolate
(TDM, also known as cord factor), and the 19kDa lipopro-
tein downregulate IFN-γ-inducible genes including those
involved in antigen presentation by MHC class II machinery
(Table 1)[ 32, 86, 94, 111, 112]. Other mechanisms that
modulate antigen presentation include antigen processing
and binding of peptides to MHC class II molecules [32,
87]. The 19kDa lipoprotein also inhibits MHC class I
antigen processing via Toll-like receptor signaling [88]. It
is probable that continuous attenuation of antigen presen-
tation through multiple mechanisms is advantageous for
slowly growing pathogens like M. tuberculosis [111, 112].
Inhibition of antigen presentation by these mechanisms
results in persistence of M. tuberculosis inside macrophages
[112].Clinical and Developmental Immunology 7
7. Dampening of Other Macrophage
Functions by M. tuberculosis Components
The two major antimycobacterial mechanisms of macropha-
ges include the generation of nitric oxide and other RNI
which exert toxic eﬀects on the bacilli and fusion of the
phagosomes containing mycobacteria with lysosomes that
is bactericidal [83, 92, 113]. The T cell-derived cytokines,
mainly IFN-γ and TNF-α, activate macrophages, which
then generate nitric oxide and other RNI by iNOS and
are mycobactericidal [83]. Direct demonstration of the
presence of nitrotyrosine, an RNI derived from tyrosine and
peroxynitrite in the lungs of infected mice, has shown that
RNI are formed in tuberculous granuloma. Furthermore,
inhibition of iNOS activity or disruption of iNOS gene,
required for the production of RNI, not only abolished the
protective eﬀect of RNI but also led to reactivation of latent
infection in mice [83]. Although these studies point towards
an essential role for iNOS in the control of both acute
and chronic persistent infection, the RNI generated through
thesemechanismsisnotsuﬃcienttoeliminatethebacterium
completely.
T h ep r o t e c t i v er o l eo fR N Ii nh u m a nT Bh a sa l s ob e e n
suggested [92, 114]. Studies have shown that M. tuberculosis
has evolved several strategies to evade the RNI toxicity. It
has been shown that iNOS, a cytoplasmic protein, may be
recruited to the phagosomes and this recruitment may be
inhibited by M. tuberculosis [115]. The M. tuberculosis gene,
alkyl hydroperoxide reductase subunit C (ahpC), detoxiﬁes,
in conjunction with some other proteins, the highly reactive
peroxynitrite anion (formed by the reaction of nitric oxide
with superoxide) [116]. Another potential mechanism for
blunting the toxic eﬀects of RNI is the presence of two
haemoglobin-like proteins encoded by glbN and glbO in M.
tuberculosis.TheglbN knockout mutant of M.bovisBCGwas
highly attenuated, and its growth, in vitro, was also inhibited
by nitric oxide under aerobic conditions [117]. Microarray
analyses have shown that more than 30 M. tuberculosis genes
are induced by RNI and hypoxia [59, 118]. Furthermore,
hypoxiaandinhibitionofrespirationbynitricoxideinducea
dormancy program in M. tuberculosis that leads to increased
survival and persistence of the pathogen in immune cells
[59, 119].
8. Phagolysosome Maturationand Its
Inhibition by M. tuberculosis Components
The phagocytosis of M. tuberculosis by macrophages is
followed by the maturation of phagosomes containing the
pathogen through a series of fusion and ﬁssion events with
several endocytic vesicles that culminate in a phagolysosome
[120, 121]. The ﬁssion-fusion events remodel the phago-
somal membrane, and the recruitment of vacuolar-proton
transporting ATPase (vH+-ATPase) lowers the internal pH
thatallowslysosome-derivedacidhydrolasestofunctioneﬃ-
ciently for their microbicidal eﬀect [122, 123]. Furthermore,
phagosome maturation is dependant on Ca+2 signaling
cascade that begins with phosphorylation of sphingosine
to sphingosine 1-phosphate by sphingosine kinase resulting
in elevation of cytosolic [Ca+2] inside macrophages due to
release of Ca+2 from intracellular stores in the endoplasmic
reticulumandcontinuesthroughCa+2-calmodulincomplex-
dependant activation of protein kinase II and phosphatidyl
inositol 3-kinase (PI-3K). The cascade culminates in phos-
phorylation of phosphatidyl inositol to phosphatidyl inositol
3-phosphate (PI-3P) by PI-3K in the phagosome membrane
and maturation of phagosome to an acidic bactericidal com-
partment (phagolysosome) after binding of early endosomal
a n t i g e n - 1( E E A - 1 )t oP I - 3 P[ 89, 124–126].
M. tuberculosis has also evolved several strategies to
avoid the destruction by lysosomal enzymes by disrupt-
ing the maturation of bacilli-containing phagosomes into
phagolysosmes [46, 90, 92, 127, 128]. Exclusion of vH+-
ATPase during maturation of phagosomes contributes to the
acidiﬁcation defect that prevents the fusion of phagosomes
with lysosomes [122]. Similarly, modulation of Ca+2 signal-
ing cascade, such as SapM-mediated hydrolysis and inacti-
vation of PI-3P, inhibits phagosome maturation leading to
enhanced intracellular survival of M. tuberculosis (Table 1)
[101, 126–128].
Other M. tuberculosis components such as ManLAM and
TDM (Table 1) also aﬀect phagosome maturation by inter-
fering with the tethering and fusion machinery of vesicular
transport in mammalian cells and promote persistence of
the bacterium inside macrophages [46, 89, 90, 93, 101].
The targets include the soluble N-ethylmaleimide-sensitive
factor-attachment protein receptors (SNAREs), the tethering
proteins (such as EEA-1), and the Rab family of GTPases [89,
120, 126, 128]. Some of the membrane traﬃcking processes
aﬀected by mycobacterial factors are also aﬀected by HIV
during viral budding and this overlap partially contributes
towardsthesynergismobservedbetweenAIDSandactiveTB
[129]. Another mechanism by which mycobacteria interfere
with phagosome maturation is by retention of the host
tryptophan aspartate rich coat protein (TACO) (homolog of
coronin-1) on the cytoplasmic side of their phagosomes that
likely inhibits the normal process of phagosome-lysosome
fusion [99]. The serine/threonine protein kinase G encoded
by pknG of M. tuberculosis (Table 1) is implicated as the
potential eﬀector of the inhibition of phagosome-lysosome
fusion [100, 111].
Another component of the antimicrobial repertoire of
macrophages includes lysosomal killing of M. tuberculosis
mediated by ubiquitin-derived peptides [130]. The ubiquiti-
nation destroys tubercle bacilli by autophagy as a ubiquitin-
derived peptide impairs the membrane integrity of M.
tuberculosis that allows nitric oxide to kill more eﬃciently.
On the contrary, decreased outer membrane permeability
protects M. tuberculosis from killing by ubiquitin-derived
peptides [131].
9. Apoptosis of InfectedMacrophages andIts
Inhibition by M. tuberculosis Components
The apoptosis of infected macrophages participates in host
defense against infection as apoptotic vesicles containing8 Clinical and Developmental Immunology
mycobacterial antigens are taken up by dendritic cells for
CD8+ T cell activation by phagosome-enclosed antigens [79,
80]. The CD8+ T cells activated by apoptotic vesicles from
M. tuberculosis-infected cells produce IFN-γ,w h i c hc a u s e s
uninfected macrophages to produce RNI to eﬀectively kill
intracellular M. tuberculosis.S e v e r a lM. tuberculosis-derived
factors are capable of modulating (activating as well as
inhibiting) the apoptosis of infected macrophages through
diﬀerential expression of proapoptotic and antiapoptotic
genes [90]. The mycobacterial components modulating
apoptosis of macrophages usually target the caspase cascade
or the one involving TLRs. The M. tuberculosis components
that inhibit apoptosis include cell wall components, Man-
LAM, virulence-related secretion system encoded by secA2
that transports superoxide dismutase (encoded by sodA)t o
control reactive oxygen intermediates, and NADH dehydro-
genase (encoded by nuoG)( Table 1)[ 91, 102, 103]. Two
secretory proteins of M. tuberculosis encoded by Rv3654c
and Rv3655c that inhibit apoptosis of macrophages have
also been identiﬁed recently [132]. By inhibiting apoptosis
of macrophages, M. tuberculosis avoids host defenses and
escapes from infected cells by causing necrotic cell death
[133].
10. Escape of M. tuberculosis from
Phagosome/Phagolysosome
Although it has been known for quite some time that
M. tuberculosis survives in the phagosome by blocking
(or slowing down) its maturation into phagolysosome and
persists, one of the mechanism by which it escapes from
phagosome/phagolysosome to infect other macrophages and
other immune/alveolar cells has been elucidated recently.
Initial subtractive hybridization-based studies identiﬁed a
genomic region, termed region of diﬀerence 1 (RD1), that
was present in all virulent M. tuberculosis and M. bovis
strains but was absent in the vaccine strain M. bovis BCG
[2, 134, 135]. Subsequently, it was shown that RD1 is crucial
for the virulence of M. tuberculosis as it encoded proteins
that formed a novel protein secretion system (ESX-1). ESX-
1 (type VII secretion system) is involved in the export of
several M. tuberculosis proteins including two potent T cell
antigens encoded by RD1 itself, the 6-kDa early secreted
antigenic target (ESAT-6) (encoded by esxA) and 10-kDa
culture ﬁltrate protein (CFP-10) (encoded by esxB) that lack
signal sequences for their export [2, 134, 136–140].
The importance of ESX-1 secreted proteins in virulence
of M. tuberculosis has been shown by deletion of RD1 or
disruption of ESAT-6 from M. tuberculosis genome that
resulted in reduced virulence (spreading) both, in cultured
macrophages and in mice [140, 141]. Furthermore, the
introduction of RD1 genes in M. bovis BCG resulted in
altered colonial morphology, increased virulence in severely
combined immune deﬁcient mice including the formation
of granuloma, and longer persistence in immunocompetent
mice [142]. In M. tuberculosis, ESAT-6 complexes with
CFP-10 in 1:1 ratio before its export outside the cell
but can dissociate from its partner (CFP-10) at lower pH.
Individually, ESAT-6, but not CFP-10, can cause disruption
of artiﬁcial membranes as well as cytolysis [143–145]. ESAT-
6 alone has also been shown to associate strongly with
liposomes containing dimyristoylphosphatidylcholine and
cholesterol (constituents of mammalian cell membranes)
and causing destabilization and lysis of liposomes [95, 96,
144].
Thestudiescarriedoutb ydeJ ongeetal.[96]haveshown
that ESAT-6:CFP-10 complex secreted by live M. tuberculosis
inside phagosome splits apart when tubercle bacilli are
stressed following acidiﬁcation of phagosome, and ESAT-6
inserts itself into lipid bilayer, causing lysis and escape of
M.tuberculosisfrom phagosome. Further studies have shown
that ESAT-6 also induces apoptosis of macrophages via the
extrinsic(caspase-dependent)pathwaybyformationofpores
in cell membrane [146] and contributes (or helps) in the
translocation of M. tuberculosis from the phagolysosomes to
the cytoplasm in myeloid cells [97]. More recently, ESAT-6
has also been shown to cause cytolysis of type 1 and type
2 alveolar epithelial cells. This ESAT-6-mediated cytolysis
was shown to help in the dissemination of M. tuberculosis
through alveolar wall [19]. The ESAT-6 homolog from
Mycobacteriummarinum,thebacteriumthatcausestubercu-
lous granuloma in zebraﬁsh, has also been demonstrated to
cause lysis of red blood cells and macrophages by forming
pores in their membranes [147, 148]. The presence of a
capsular layer containing high amounts of proteins that are
secreted via the ESX-1 secretion system including ESAT-
6 has also been demonstrated in pathogenic mycobacteria
recently [98]. Furthermore, ESX-1-associated proteins in the
capsular layer enhanced the interaction of mycobacteria with
macrophages and also dampened proinﬂammatory cytokine
response of macrophage. These studies have established
the role of ESX-1 secretion system and ESAT-6 protein
of M. tuberculosis in facilitating macrophage infection and
subsequent bacterial escape to infect other nearby cells
(Table 1).
11. PersistenceandReactivation of
LatentTBInfection
The hallmark of M. tuberculosis infection in humans is
the inability of an otherwise eﬀective immune response
to completely eliminate the pathogen. The tubercle bacilli
have evolved multiple strategies to manipulate infected host
cells in order to evade or modify the ensuing immune
response so as to avoid elimination and thus persist in the
host. As described above, several M. tuberculosis factors,
ManLAMand19-kDalipoproteinnotableamongthem,have
been identiﬁed that modulate antigen presentation pathways
and either blunt the microbicidal functions of macrophages
and other immune cells (such as RNI) or prevent their
maturation (phagolysosome) (Table 1).
Twoexperimental strategieshavebeenemployedtoiden-
tify other M. tuberculosis factors, which promote persistence
of the pathogen in immune cells including macrophages.
One approach involves cloning of M. tuberculosis genes in
nonpathogenic mycobacteria and studying their increasedClinical and Developmental Immunology 9
survival in macrophages or other mammalian cells while
the other approach uses knockout mutants of M. tubercu-
losis for selected genes for persistence of the pathogen in
macrophages and other immune cells. Several additional
M. tuberculosis factors promoting persistence or increased
survival in mammalian cells have been identiﬁed. Some of
these factors include phospholipases encoded by plcA, plcB,
plcC, and plcD [149], the two PhoP and PhoQ regulatory
proteins [21], phosphate-binding proteins PstS1 and PstS2
[150] ,a n dp r o t e i n se n c o d e db ymce operons [151]. Thus,
M. tuberculosis has devoted a large part of its genome
towards functions that promote its intracellular survival in
mammalian cells including macrophages.
Reactivation of latent infection requires latent M. tuber-
culosis cells to exit dormancy. Several factors can trigger
the development of active disease from the reactivation of
remote infection, and this typically involve the weakening
of the immune system. HIV infection is the most important
single risk factor for progression to active disease in adults
as it causes depletion of CD4+ T cells and functional
abnormalities of CD4+ and CD8+ T-cells which play an
important role in providing protection against active TB
disease [4, 6]. Likewise, M. tuberculosis infection accelerates
the progression of asymptomatic HIV infection to acquired
immunodeﬁciency syndrome (AIDS) and eventually to
death. This is recognized in the current AIDS case deﬁnition
aspulmonaryorextrapulmonaryTBinHIV-infectedpatient
is suﬃcient for the diagnosis of AIDS. Old age, malnutrition,
andmedicalconditionsthatcompromisetheimmunesystem
such as poorly controlled diabetes mellitus, renal failure, and
therapywithimmunosuppressivedrugsareotherfactorsthat
lead to immunodepression and reactivation of a dormant
infection [6, 8, 152, 153]. The reactivation TB can occur in
any organ system in which the tubercle bacilli were seeded
during the primary infection; however, in immunocompe-
tent individuals, the reactivation usually occurs in the upper
lobes, where higher oxygen pressure supports good bacillary
growth. The lytic transglycosylases known as resuscitation
promoting factors (RPFs) and an endopeptidase (RipA)
of M. tuberculosis have recently been recognized as vital
components for revival from latency [154–156].
12. CurrentDynamicModel of LatentInfection
The LTBI has traditionally been deﬁned as infection with
M. tuberculosis in foci within granuloma that remain in
nonreplicating state but retain their ability to come out
of latency and cause active TB if and when a disruption
of the immune response occurs [57]. However, recent
experimental data supports a dynamic model of LTBI where
endogenous reactivation as well as damage response occurs
constantly in immunocompetent individuals [157]. The
model suggests that during infection, M. tuberculosis grows
well inside phagosomes; however, some bacilli released from
necrotic macrophages in extracellular milieu in developing
granulomas stop replicating. The arrest of bacterial growth
occurs even before an eﬀective immune response has fully
been developed due to hypoxic and acidic environment
(conditions that mimic stationary bacterial cultures) in
the extracellular milieu and release of bactericidal enzymes
from dead macrophages and neutrophils. The actively
growing bacillary population is eventually killed due to the
development of an eﬀective immune response; however,
nonreplicating bacilli resist killing and survive [158, 159].
The model further suggests that some macrophages
(foamy macrophages) also emerge during the chronic
inﬂammatory process, as they have phagocytosed the cellular
debris rich in fatty acids and cholesterol derived from
cellular membranes [160, 161]. The foamy macrophages also
phagocytose extracellular nonreplicating lipid-rich M. tuber-
culosis; however, the bacilli do not grow in the intracellular
environmentofactivatedmacrophagesbutarealsonotkilled
due to the nonreplicating state of the bacilli [162]. The
nonreplicating bacilli-laden foamy macrophages drain from
lung granuloma towards the bronchial tree and return to a
diﬀerent region of lung parenchyma due to aerosols gener-
ated by inspired air and begin the infection process at this
newlocationonceagain[157,160,161,163].Inthisdynamic
process, reinfection in the upper lobe may have the chance to
cause cavitary lesion. This is aided by higher oxygen pressure
in the upper lobes that can support rapid extracellular
bacillary growth resulting in bacillary concentration that can
not be controlled by the optimum immune response by the
host. The subsequent much stronger inﬂammatory response
leads to tissue destruction, liquefaction, and extracellular
bacillary growth which ampliﬁes the response further and
causes cavitation [157, 158].
The dynamic infection process leading to active dis-
ease in the upper lobes has some parallels with immune
reconstitution inﬂammatory syndrome and the active TB
disease that occurs in HIV-infected patients. The presence
of bacilli is tolerated by the HIV-infected patients with
low CD4+ cell counts as the host is unable to mount
an inﬂammatory response needed to control their growth.
However, the sudden increase in CD4+ T cells in AIDS
patients receiving highly active antiretroviral treatment
causes an aggressive granulamatous response and active
TB disease [164, 165]. The possibility of slow clearance of
latent infection proposed by the dynamic infection model
has also been supported by a recent study from Norway
comprisingapopulationofindividualsexposedtoaminimal
risk of active transmission of infection. Cohort analysis
of data from National Tuberculosis Registry to calculate
rates and changes in rates of active TB disease, among
patients previously exposed to M. tuberculosis, has shown
that the rate of reactivated TB has progressively decreased
overtime [166].Thestudyfurthersuggestedthatthenumber
of individuals with latent infection could be reduced in
half in approximately 9 years in populations in which new
infections are eﬀectively prevented. The dynamic infection
model also explains how therapy for a relatively short
time (9 months) with a single drug (isoniazid), active only
against actively dividing bacilli [167], is highly eﬀective for
a latent infection that can possibly remain dormant for
the entire lifetime of the host. As isoniazid will prevent
episodesofreinfectionbybacilliresuscitatedfromdormancy,
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the stomach will eventually lead to clearance of latent
infection [157, 166].
13. Diagnosisof Latent
M. tuberculosis Infection
The persons infected with M. tuberculosis may be identiﬁed
by tuberculin skin test six to eight weeks after exposure to the
bacilli. The test is based on a delayed-type hypersensitivity
(DTH) response to a complex cocktail of M. tuberculosis
antigens, known as puriﬁed protein derivative (PPD). The
induration of more than 5mm, recorded 48 to 72 hours
after injection of PPD, is considered as positive. Surveys
conducted with PPD skin test suggest that nearly a third
of the world’s and half of Asia’s population is infected with
M. tuberculosis [5]. Skin test reaction over 20mm is usually
due to active disease; however, a negative skin test in an
active TB patient may also result from anergy or incorrect
administration of the test. The tuberculin skin test lacks
sensitivity and speciﬁcity as it can not diﬀerentiate between
infection with M. tuberculosis and sensitization with other
environmental mycobacteria [5, 8]. Also, BCG vaccination
may cause false-positive reactions, but these generally last
only a few years after vaccination and are in the moderate
range (5 to 10mm).
More sensitive and speciﬁc tests such as cell-mediated
immunity-based interferon-gamma (IFN-γ) release assays
(IGRAs)havealsobeendevelopedthatdetectTcellresponses
after stimulation by two M. tuberculosis-speciﬁc antigens,
early secreted antigenic target-6 (ESAT-6) and culture ﬁltrate
protein-10 (CFP-10) [168–173]. The IGRAs have excellent
speciﬁcityastheantigens(ESAT-6 andCFP-10) used in these
assays are encoded by genes deleted in the vaccine strain
M. bovis BCG and majority of environmental mycobacteria
of clinical relevance [134, 135, 170]. Another variation
of conventional IGRAs has also been developed by using
ﬂow cytometry [174]. Although ﬂow cytometric approach
has an advantage over conventional IGRAs as a smaller
blood volume (<1ml) is required for testing, the assay has
limited utility in much of the developing world due to the
requirement of technical expertise and the high cost of ﬂow
cytometers. The detection of signiﬁcant levels of antibodies
to some M. tuberculosis-speciﬁc proteins has also been noted
in latently infected individuals as well as in patients with
active TB disease but not in healthy subjects [175–178].
However, antibody-based tests have not been used so far for
the detection of LTBI.
TwocommercialIGRAs,wholeblood,ELISA-basedQuan-
tiFERON (QFN)-TB Gold assay (Cellestis Ltd., Carnegie,
Australia) and peripheral blood mononuclear cell (PBMC)
and enzyme-linked immunospot (ELISPOT) technology-
based T SPOT-TB (Oxford Immunotec, Oxford, UK) test
have also been developed and approved by Food and Drug
Administration (FDA) for detecting LTBI. The tests were
initially based on stimulation of T lymphocytes with ESAT-6
and CFP-10 proteins and measurement of IFN-γ production
(QFN-TB Gold) or detection of T-cells themselves (T SPOT-
TB). These tests have undergone further improvement. The
newer version of the QFN-TB Gold is called QuantiFERON-
TB-Gold-In-Tube (QFT-G-IT) (Cellestis Ltd., Carnegie,
Australia) that uses ESAT-6 and CFP-10 and TB7.7 (corre-
sponding to Rv2654 [2]) peptides as antigens. The newer
version of T-Spot-TB also uses peptides of ESAT-6 and CFP-
10 instead of whole ESAT-6 and CFP-10 proteins as antigens
(Oxford Immunotec, Oxford, UK). The performance of
both QFT-G-IT and T-Spot-TB tests have recently been
evaluated extensively, and several systematic reviews are
available for a more detailed description [173, 179–182].
Although IGRAs can not distinguish between LTBI and
activeTBdiseaseinimmunocompetentadults[173],inhigh-
risk individuals with immunosuppressive conditions and
children, IGRAs may help in the diagnosis of active disease
as adjunctive diagnostic tests, particularly if specimens from
the suspected site of infection (such as bronchoalveolar
lavage, cerebrospinal ﬂuid) rather than blood is used [183,
184]. While the results of IGRAs exhibit better correlation
with surrogate measures of exposure to M. tuberculosis in
low TB incidence countries; however, their performance is
suboptimal in countries with a high TB incidence [173, 180–
182, 185].
In low TB incidence countries of North America and
WesternEurope,themajorityofactiveTBdiseasecasesoccur
in foreign-born persons. Previous studies have shown that
majority of active disease cases in immigrants/expatriates
originating from TB endemic countries occur as a result of
reactivation of previously acquired infection mostly within
two years of their migration [8, 12, 171, 172]. Application
of IGRAs to identify latently infected individuals and their
treatment for LTBI has greatly helped in lowering the inci-
dence of TB in rich, advanced countries [171, 172, 182, 186,
187]. Some other low-intermediate TB incidence countries
which contain large expatriate populations originating from
TB endemic countries [188–192] are also evolving similar
strategies for controlling TB [12, 193].
14. Conclusions
With nearly 9 million new active TB cases and 2 million
deaths occurring every year, TB remains a major infectious
disease of global proportion. Active disease patients with
sputum smear-positive pulmonary TB are the main source
of infection. Primary infection with M. tuberculosis leads to
clinical disease in ∼10% of individuals. In the remaining
cases, the ensuing immune response arrests further growth
of M. tuberculosis. However, the pathogen is eradicated com-
pletely in ∼10% people while the immune response in the
remaining ∼90% individuals only succeeds in containment
of infection as some bacilli escape killing by blunting the
microbicidal mechanisms of immune cells and remain in
nonreplicating (dormant or latent) state in old lesions. The
dormant bacilli retain their ability to induce reactivation
and to cause active TB if a disruption of immune response
occurs. While active transmission is a signiﬁcant contributor
of active disease cases in high TB burden countries, most
cases in low TB incidence countries arise from this pool
of latently infected individuals. The positive tuberculin skinClinical and Developmental Immunology 11
test or more recent and speciﬁc T cell-based IGRAs in a
person without overt signs of the disease indicates LTBI.
Two commercial IGRAs, QFT-G-IT and T-Spot-TB, are
also available. Application of IGRAs to identify latently
infected individuals and their treatment for LTBI has greatly
helped in lowering the incidence of TB in rich, advanced
countries. Similar approaches also hold great promise for
other countries with low-intermediate rates of TB incidence.
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